MUC1 and lung carcinoma: Taken together, the malaria parasite may be an ideal vaccine vehicle not only for presentation of lung cancer antigens (such as MUC1) to tumor-specific T-cells, but also act as an adjuvant to provide the appropriate milieu to enhance the efficacy of these effector cells [43]–[45].